Literature DB >> 33807519

Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology.

Theodoros Karantanos1, Tania Jain1, Alison R Moliterno2, Richard J Jones1, Amy E DeZern1.   

Abstract

Chronic myeloid neoplasms are clonal diseases with variable clinical course and outcomes and despite the introduction of novel therapies, patients with high-risk disease continue to have overall poor outcomes. Different groups have highlighted that men have overall worse survival and higher incidence of transformation to acute leukemia compared to women across neoplasms such as myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), MDS/MPN overlap neoplasms, and CML. More recent studies evaluating the genomic profile of patients with these neoplasms demonstrated a male predominance for mutations in high-risk genes including ASXL1, U2AF1, SRSF2 and ZRSR2. The understanding of the underlying biology is limited but a number of hypotheses have been developed and are currently being investigated. This review summarizes the current knowledge about sex-related differences in the clinical outcomes and genomic profile of patients with chronic myeloid neoplasms and discusses the hypothesized biologic mechanisms as an attempt to explain these observations.

Entities:  

Keywords:  MDS; MPN; myeloid neoplasms; sex-related differences

Mesh:

Year:  2021        PMID: 33807519      PMCID: PMC7961949          DOI: 10.3390/ijms22052595

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  60 in total

1.  On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs.

Authors:  D V Santi; C E Garrett; P J Barr
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

2.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

3.  Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.

Authors:  Brady L Stein; Donna M Williams; Ophelia Rogers; Mary Ann Isaacs; Jerry L Spivak; Alison R Moliterno
Journal:  Exp Hematol       Date:  2010-10-01       Impact factor: 3.084

4.  Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes.

Authors:  T Nösslinger; H Tüchler; U Germing; W R Sperr; O Krieger; D Haase; M Lübbert; R Stauder; A Giagounidis; P Valent; M Pfeilstöcker
Journal:  Ann Oncol       Date:  2009-07-15       Impact factor: 32.976

5.  Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms.

Authors:  Brady L Stein; Alfred Rademaker; Jerry L Spivak; Alison R Moliterno
Journal:  Thrombosis       Date:  2011-07-24

6.  Gender differences in lung cancer risk by smoking: a multicentre case-control study in Germany and Italy.

Authors:  M Kreuzer; P Boffetta; E Whitley; W Ahrens; V Gaborieau; J Heinrich; K H Jöckel; L Kreienbrock; S Mallone; F Merletti; F Roesch; P Zambon; L Simonato
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

7.  Escape from X inactivation varies in mouse tissues.

Authors:  Joel B Berletch; Wenxiu Ma; Fan Yang; Jay Shendure; William S Noble; Christine M Disteche; Xinxian Deng
Journal:  PLoS Genet       Date:  2015-03-18       Impact factor: 5.917

8.  The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study.

Authors:  Margherita Perricone; Nicola Polverelli; Giovanni Martinelli; Lucia Catani; Emanuela Ottaviani; Elisa Zuffa; Eugenia Franchini; Arbana Dizdari; Dorian Forte; Elena Sabattini; Michele Cavo; Nicola Vianelli; Francesca Palandri
Journal:  Oncotarget       Date:  2017-06-06

9.  Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.

Authors:  Lingxu Jiang; Yingwan Luo; Shuanghong Zhu; Lu Wang; Liya Ma; Hua Zhang; Chuying Shen; Wenli Yang; Yanling Ren; Xinping Zhou; Chen Mei; Li Ye; Weilai Xu; Haiyang Yang; Chenxi Lu; Jie Jin; Hongyan Tong
Journal:  Cancer Sci       Date:  2019-12-24       Impact factor: 6.716

10.  Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation.

Authors:  Silvia Mas-Peiro; Jedrzej Hoffmann; Stephan Fichtlscherer; Lena Dorsheimer; Michael A Rieger; Stefanie Dimmeler; Mariuca Vasa-Nicotera; Andreas M Zeiher
Journal:  Eur Heart J       Date:  2020-02-21       Impact factor: 29.983

View more
  3 in total

1.  The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia.

Authors:  Theodoros Karantanos; Patric Teodorescu; Brandy Perkins; Ilias Christodoulou; Christopher Esteb; Ravi Varadhan; Eric Helmenstine; Trivikram Rajkhowa; Bogdan C Paun; Challice Bonifant; W Brian Dalton; Lukasz P Gondek; Alison R Moliterno; Mark J Levis; Gabriel Ghiaur; Richard J Jones
Journal:  Sci Adv       Date:  2022-02-18       Impact factor: 14.136

Review 2.  Extracellular Vesicles in Myeloid Neoplasms.

Authors:  Christina Karantanou; Valentina René Minciacchi; Theodoros Karantanos
Journal:  Int J Mol Sci       Date:  2022-08-08       Impact factor: 6.208

Review 3.  1Menstruation: a possible independent health promoter, aging and COVID-19.

Authors:  Alireza Bolourian; Jay Shen; Marjan Gharagozloo; Zahra Mojtahedi
Journal:  Caspian J Intern Med       Date:  2022
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.